Business Context and Reporting Period
This Form 8-K is filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) for the reporting period of May 18, 2021. The company is a Delaware corporation focused on developing next-generation engineered coagulation Factor VIIa (FVIIa) therapies.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the initiation of dosing in the Company's Phase 1/2 clinical study (MAA-202) for marzeptacog alfa (activated), also known as "MarzAA." Key details include:
- Product: A subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa.
- Study Scope: The study targets patients with Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A treated with Hemlibra.
- Milestone: The first patient was dosed on May 18, 2021.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the clinical milestone. It does not provide updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the inherent uncertainties of clinical trials. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study design and patient inclusion criteria.
- Review the company's most recent 10-Q or 10-K filing for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor future 8-K filings for updates on the MAA-202 study progress, including safety and efficacy data readouts.
- Confirm the regulatory status of marzeptacog alfa (activated) with the FDA or relevant health authorities.